Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction

Hypertension Research

Volumn 33, Issue 1, 2010, Pages 62-66

  Ito, Sadayoshi ^a   Nakura, Noriko ^b   Le Breton, Stephanie ^c   Keefe, Deborah ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Direct renin inhibitor; Renal dysfunction; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; CREATININE; PLACEBO; POTASSIUM;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; BRAIN INFARCTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; HUMAN; HYPERTENSION; JAPANESE; KIDNEY DYSFUNCTION; MALE; MEAN ARTERIAL PRESSURE; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; PULSE RATE; RHINOPHARYNGITIS; SIDE EFFECT; SUPRAVENTRICULAR PREMATURE BEAT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD CHEMICAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; YOUNG ADULT;

EID: 74349119971     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.175     Document Type: Article

References (28)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
2. Wong ND, Lopez VA, L'Italien GL, Chen R, Kline S, Franklin S. Inadequate control of hypertension in US adults with cardiovascular disease co morbidities in 2003-2004. Arch Int Med 2007; 167: 2431-2436.
3. Salvetti A, Mattei P, Sudana I. Renal protection and antihypertensive drugs. Drugs 1999; 57: 665-693.
4. Ferrario C. Role of angiotensin II in cardiovascular disease-therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7: 3-14.
5. Chobanian A, Bakris G, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
6. Jensen C, Herold P, Brunner H. Aliskiren: the first renin inhibitor for clinical treatment. Nature Rev 2008; 7: 399-410.
7. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angio-tensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492-2499.
8. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-E8.
9. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
10. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
11. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemure S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
12. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
13. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29: S1-S106.
14. Oh B, Mitchell J, Herron J, Chung J, Khan M, Keefe DL. Aliskiren, an oral rennin inhibitor provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
15. Susic D, Frohlich E. Nephroprotective effect of antihypertensive drugs in essential hypertension. J Hypertens 1998; 16: 555-567.
16. Abbott K, Basta E, Bakris L. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol 2004; 44: 431-438.
17. Vaidyanathan S, Bigler H, Yeh C, Bizot M, Dieterich H, Howard D, Dole W. Pharma-cokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46: 661-675.
18. Hoyer J, Schulte KL, Lenz J. Clinical pharmacokinetics of angiotensin converting enzyme inhibitors in renal failure. Clin Pharmacokinet 1993; 24: 230-254.
19. Kean WF, Eknoyan G. Proteinurai, albuminuria, risk, assessment, detection (PARADE): positional paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-1010.
20. McMurray JV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
21. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. NEJM 2008; 358: 2433-2446.
22. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DM, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 Rats. Hypertension 2008; 52: 130-136.
23. Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117: 3199-3205.
24. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety and efficacy of aliskiren, an oral direct renin inhibitor, in japanese patients with hypertension. J Clin Hypertens 2007; 9 (5 suppl A): A169. Abstract P-406.
25. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct rennin inhibitor, and rampipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
26. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73: 719-725.
27. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood Jr WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfield J. Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131: 350-355. (Pubitemid 26043397)
28. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH. Time course of the antiproteinuric and anti-hypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73: 1419-1425.